Ovarian cancer

Why we focus on ovarian cancer

There are around 7,400 new ovarian cancer cases in the UK every year, and this cancer type is the 6th most common cause of cancer mortality in females in the UK. There is no screening technique, and most patients (~60%) present with advanced disease because symptoms are not easy to recognise or distinguish from other, less serious conditions, often leading to late or mis‑diagnosis. Ovarian cancer survival is improving in the UK and has almost doubled in the last 40 years, and when diagnosed at its earliest stage, 93% of people with ovarian cancer will survive their disease for five years or more. Sadly, only 13% of people survive ovarian cancer when it is diagnosed at the latest stage. Therefore, there is a great need to develop new therapies for this disease, based upon greater understanding of its biology.

What we do
  • Our focus is on translational research, aimed at developing new treatments for women with ovarian cancer
  • We aim to understand the links between cancer and inflammation
  • We are investigating the impact of modulating the tumour-promoting cells and mediators of inflammation
  • Viral gene therapies are being developed
  • We are investigating the interaction of oncolytic viruses with the host immune system
  • We are exploring the relationship between cellular DNA damage repair and adenovirus biology, particularly homologous recombination
  • Novel agents are being tested in Phase I and II clinical trials.
Major Funders
  • Cancer Research UK
  • BBSRC
  • Medical Research Council
  • Ovarian Cancer Action
  • Wellbeing of Women
Key Publications
Address

Barts Cancer Institute,
Queen Mary University of London,
Charterhouse Square,
London EC1M 6BQ

Email address: bci-admin@qmul.ac.uk
Telephone: +44 20 7882 5555

Upcoming Events

© 2013 ~ 2022 Cancer Research UK Barts Centre